lindas have a posse
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am very happy to own Northwest Biotherapeutics as are the others who bought into this wonderful company. The shareholder count went from around 150 in 2019 to 45K today. The majority of them voted to support management at the 2022 ASM. There's zero evidence of discontent though you can continue to fabricate straw man arguments. They really are not effective.
We are not here to disprove your straw man argument.
All market makers, broker dealers, and proprietary trading firms have a risk department tasked to ensure illegal trading patterns like spoofing does not occur. The idea that they could blame the customer isn't rational or legal. They know we have the evidence so they're looking for a fall guy to minimize their exposure. It will likely be a software glitch in the risk department combined with a lone wolf trader or portfolio manager leading a team of traders.
None of the market makers really want their customers to be pulled into this as they want to maintain those relationships. Blame will be found internally in my opinion. The defense are simply stalling, when mentioning their customers, in order to see how far we are willing to take this lawsuit.
If this was a convertible loan then there would be criticism about dilution. Since there isn't it's about the terms of the loan. Some cannot be pleased but thankfully management are focused on delivering DCVax for patients not shrieks from the peanut gallery.
The 10% premium is added to the principal of the loan initially not every month. In total the firm pays only about 600K in interest in a 12 million dollar loan. We are not beginning payments until November. To call this usury, extortion, or inappropriate is silly. The firm has no cash on hand, no revenue, and isn't past approval process. The fact that Fife isn't asking for shares or any collateral means he has very high confidence in Northwest Biotherapeutics management. If others on this forum want to lend the firm money at better rates then please contact Les Goldman lgoldman@nwbio.com!
Excellent Press Release. Thank you Dave Innes.
As Dave Innes told me on 5/10 shorts always try to turn your best day into your worst.
14 months of loan amortization results in about 600K in interest paid to the lender. Fife certainly isn't getting a 30% return on this loan. It's really hilarious how the best news always gets spun into an existential crisis.
So annoying that we have to field such ridiculous questions regarding the world-class management team at Northwest Biotherapeutics.
Fife's loan was obviously deposited into a UK bank not some San Francisco VC fund for failed startups. Sorry, we have Landmark Trial Data not mouse studies. When bubbles pop some ridiculous ideas fail. Northwest Biotherapeutics has the longevity of a German Cockroach. Impossible to kill this firm. Many have tried.
Good buy. Shorts think that longs are upset about these low prices though they will not last much longer.
How dare you ruin one of the greatest songs, jackass!
Sorry you had to sell Danish Dude. I greatly enjoyed your posts as did many NWBO longs. Hopefully you are able to resolve your difficulties and buy back into NWBO in the future. Best wishes!
None of the PMs mentioned glioblastoma specifically either. I wouldn't feel dismayed as the debate was about how the UK government can facilitate more rapid drug discovery through policy initiatives. If DCVax are before MHRA and NICE then it could be inappropriate for MPs to mention it at this stage before regulators make a decision.
The SAP was accepted by all four regulatory authorities. It's very laughable that you're still playing this broken record in an endless repetitive loop.
Markets misprice valuable assets all of the time. Such ignorance explains why the class of value investors exist. Only a neophyte would look at Northwest Biotherapeutics after releasing Landmark Trial Data then think this misappropriation will continue indefinitely.
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
https://www.researchsquare.com/article/rs-2591941/v1
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169815671
Having an idea, proving it in a Landmark PIII trial, publishing it in JAMA, and getting it to market are not all the same thing. Did you have some mouse studies you want to cite as well?
Shorts don't want longs to defend the company. The stock gets manipulated then they gaslight supporters or worse. It's not a sustainable strategy as Linda Powers has an endless supply of investors willing to lend her money until DCVax achieves imminent approval. Once that occurs there will be a delgue of investors piling into Northwest Biotherapeutics. Then the minority of critics will seem more like the charlatans who they are in reality. In my opinion the smoke screen will evaporate quickly and we will see who's naked.
GlassJoe, if you imagine regulators in the US, EU, and Canada are going to let their GBM patients die while UK patients live longer lives thanks to MHRA expediency well that's an entirely irrational conclusion. One only has to look at the Covid vaccine approval to see how quickly global approval can occur once a single jurisdiction provides the first approval.
My adoration results from the ingenious innovators leading Northwest Biotherapeutics into the greenfield trillion dollar all solid tumors market.
You imagine irrational scenarios then get a dose of reality.
This is rather moot since DCVax will be approved in US, Canada, and the EU after UK gives approval this year. The idea we will be in some limbo stage isn't rational. Glioblastoma is an orphan disease while DCVax has no side effects.
It would make zero sense for management to allocate resources on cold storage facilities which would go unused. So the amount of cold storage provides great insight into how much revenue management expect Sawston will bring to Northwest Biotherapeutics shareholders. The question remains how much turnover there will be in the cold storage facilities. I believe the trial dosage protocol gives us insight.
Sawston has cold storage for $60B in DCVax doses. We are easily a $100B company over a medium term 5 year time horizon.
On UK approval I expect we will be above $15. With rest of the world I believe double that around $30. After two years of producing DCVax $50-75. Upon initial data from other DCVax trials we should be at $100. Though this could all come sooner than expected given the risk to reward ratio heavily skews towards exponential return possibilities. Even in a bear market where safe investments like bonds pay a good return there's always going to be those wanting to be part of our Cinderella Story. Northwest Biotherapeutics are the culmination of decades of oncology failures. We are the platform technology for all tumors! There's no limit to our upside or clearly velocity on how quickly our price can appreciate. No comparative data. We only need to wait and let management do their job.
Linda Powers happens to be the ONLY CEO to ever show clinicial results in nGBM and rGBM.
She's a leader with decades of innovative experience.
I trust the National Academy of Sciences when they state regarding Linda Powers:
She was co-lead negotiator for the U.S. on the North American Free Trade Agreement, financial sector agreement, which opened banking, securities, insurance, pension fund and related opportunities in Canada and Mexico.
During the 1980s, Ms. Powers practiced law, specializing in corporate mergers, acquisitions and financings, and certain kinds of intellectual property transactions. While working for the headquarters of the European Union in Brussels, she was responsible for drafting the initial intellectual property rules that now govern know-how licensing in the European Union.
Management delivered an autologous life-saving cancer vaccine at a lower price to develop than the typical drug. They also invented several manufacturing processes, secured hundreds of patents, and published one of the most read JAMA articles ever to grace that most prestigious publication.
It's amazing to see our shareholder count increase exponentially in only 3 years from around 150 in 2019 to 45K as of 2022. Let's all remember that excellence takes time. Some don't have the patience to reap the rewards. Management did it for the patients not those looking for a quick swing trade. Thankfully the vast majority of shareholders are 100% behind our world-class management team.
As Warren says don't buy a company you won't hold for at least five years!
Let's hear from billionaire Robert Hefner who knows a thing or two:
Our Northwest Biotherapeutics (NWBO) investee “partner” likely has just made one of the biggest breakthroughs in the history of cancer. We know that is a really big statement so why do we at GHK believe that is possible? Because we believe the doors through which major cancer breakthroughs must pass are the human immune system, immunotherapies and personalized vaccines and NWBO has just leaped through those doors with its personalized DCVax vaccine made from your own cells.
You can argue about trial statistics until the cows come home but the bottom line is 1) people living longer 2) quality of life during treatments and 3) the cost of treatments.
During NWBO’s 16-year Phase III trial to treat glioblastoma (GBM), one of the most difficult and lethal of all solid tumor cancers 1) more people lived longer, 2) it is safe with virtually no side effects occurring and 3) NWBO estimates treatments will cost about half as much as Standard of Care chemotherapy and radiation treatments. So for the first time ever, GBM patients can have hope! And can hope like prayer increase the effectiveness and energy of the immune system? We think so.
We are aware we stuck our necks out when we said “possibly one of the biggest breakthroughs in the history of cancer”. So we have listed below our three principle reasons so you can decide for yourself:
After 417 failed GBM trials treating 31,952 patents over decades, DCVax-L is first treatment that gives GBM patients a meaningful chance to live longer, some now living 9 to as many as 19 years and counting.
DCVax was conceived and created not for glioblastoma alone but as a personalized tool of your own immune system to defeat all solid tumor cancers and that’s 90% of all cancers.
Since DCVax’s creation NWBO has amassed an enormous rich databank containing masses of information on patients, treatments, and DCVax’s use against 15 different solid tumor cancers that has not yet been analyzed by artificial intelligence (AI). We believe that in the near future when these vast amounts of data and information are teamed with AI and some of the world’s leading scientists and doctors that future generations of DCVax vaccines and protocols will experience great leaps forward in effectiveness at lower and lower costs for 90% of all cancers.
So to sum up, we believe NWBO with its DCVax immunotherapy personalized vaccines has leaped through the doors and will play a vital role in humanities great drive to defeat cancer once and for all.
Dr. Ashkan is the genius behind this viral vid of him performing brain surgery while his patient was awakened to play the violin…mid-surgery. He told me he champions DCVax-L bc of trial data along with what he’s seen first-hand from his patients. $NWBOhttps://t.co/XFTeSPFtH5
— Wade Kovash (@wkovash) June 6, 2022
Watch one of the world’s preeminent neurosurgeons explain the significance of $NWBO ‘s Phase III trial of DCVax-L. The results are groundbreaking and represent an enormous advancement in one of the most tragic cancers. https://t.co/eQw5tAsivK
— Wade Kovash (@wkovash) June 6, 2022
You mean less than a month since the final MHRA inspection and only a few months since the most read JAMA paper ever.
There's nothing toxic about giving Northwest Biotherapeutics 11 million dollars to get DCVax in the hands of GBM clinicians. In return NWBO pays interest. There's no reason for Linda Powers to dilute further when the lender has zero risk of default on the loan. We have Landmark Trial Data and Imminent Regulatory Approval.
Non convertible loan no dilution. Fife loves DCVax as does MHRA.
NWBO longs will not capitulate
Glad to hear you see the deep value in NWBO stock.
DCVax will put Novocure out of business so obviously their management team should sell as much stock as possible for compensation as it has no inherent staying power in the oncology marketplace.
Linda Powers Best CEO.
$1M a year for Optune without efficacy data even close to DCVAx.
Novocure management know all of their market share will be taken by DCVax.
The brain microwave has no future.
Management teams that dump common shares as part of their compensation clearly do not have any faith in the long-term future of the company they claim to lead.
Wrong. Form 4 does not indicate they sold to cover tax losses. They have been selling all year, son.
How many more times will Novocure management sell stock this month of March 2023??? I think a lot. DCVax.